MarketCap NL

NL Netherlands


Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.


Pharvaris is a patient-driven biopharmaceutical company with an innovative methodology to unravel the complexity of auto-immune disorders. A pioneering approach to drug development that focuses on specifically targeting and understanding the underlying cause of auto-immune diseases has been the cornerstone of Pharvaris’ vision. Since its inception, the company has been making impressive strides in terms of scientific innovation and developing effective treatments.

Pharvaris is dedicated to advancing treatments for organ-specific auto-immune diseases that currently lack therapeutic options. We strive to leverage both scientific and business acumen, to develop better and safer treatments.

Pharvaris’ long-term goal is to become a global leader in the research, development, and commercialization of treatments for chronic rare auto-immune conditions.

Key Team

Ms. Joan Schmidt J.D. (Chief Legal Officer)

Dr. Morgan Conn Ph.D. (Chief Bus. Officer)

Maryann Cimino (Director of Corp. Relations)

Mr. Wim Souverijns Ph.D. (Chief Community Engagement & Commercial Officer)

Dr. Peng Lu M.D., Ph.D. (Chief Medical Officer)

Dr. Anne Lesage Ph.D. (Chief Early Devel. Officer)

Ms. Annick Deschoolmeester (Chief HR Officer)

Recognition and Awards
Pharvaris has been recognized as one of the fastest growing companies in Europe with several notable awards, including the EY Entrepreneur Of The Year Dutch National Finalist in 2020 and Deloitte Fast50 Technology Award in 2021.

Leadership team

Mr. Berndt Axel Edvard Modig CPA, M.B.A., MBA (Co-Founder, CEO & Exec. Director)

Ms. Anna Nijdam M.Sc., R.A. (Head of Fin. & Principal Accounting Officer)

Dr. Jochen Knolle Ph.D. (Chief Scientific Officer & COO)

Products/ Services
Biotechnology, Life Science, Pharmaceutical
Zug, Zug, Switzerland
Company Registration
SEC CIK number: 0001830487
Traded as
Social Media
Mon Feb 26 2024

businessabc offers a global business, SMEs wiki directory blockchain, NFTs, AI powered marketplace for businesses worldwide.

Follow Us
Produced by
In collaboration with

Copyright 2023 © businessabc powered by ztudium